We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GPhA Petitions FDA for Same-Name Biosimilars
GPhA Petitions FDA for Same-Name Biosimilars
September 30, 2013
In an effort to avoid confusion that could jeopardize patient safety and access, biosimilars should have the same international non-proprietary name (INN) as the biologic they refer to, GPhA asserts in a citizen petition filed Sept. 17.